Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Market Access
  • Medicare Advantage Insurers Will See Higher Payments as CMS Backs Off a Key Payment Update
  • Market Access

Medicare Advantage Insurers Will See Higher Payments as CMS Backs Off a Key Payment Update

KFF Medicare

The Trump administration this week backed off a key element of its Medicare Advantage rate proposal, resulting in billions of dollars in additional payments to private insurers.

Market AccessRead full story

pharminent April 8, 2026 (Last updated: April 8, 2026)

KFF Medicare

The Trump administration this week backed off a key element of its Medicare Advantage rate proposal, resulting in billions of dollars in additional payments to private insurers.

Market AccessRead full story

Post navigation

Previous: Sidewinder pockets $137m in Series B to take bispecific ADCs to clinic
Next: Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities

Related Stories

  • Market Access

How cost and perception could reshape the GLP-1 market

pharminent August 21, 2026
  • Market Access

D.C. Circuit Affirms HHS Authority Over 340B Rebate Models

pharminent July 24, 2026
  • Market Access

NICE aims to cut funding for Amgen lung cancer drug Lumykras

pharminent July 9, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.